ArticleJournal of translational medicine2026
Activation of NF-κB signaling pathway in GSDME-low esophageal squamous cell carcinoma cells enhances radioresistance.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundRadioresistance in esophageal squamous cell carcinoma (ESCC) contributes to locoregional recurrence and radiotherapy failure. Radiotherapy has been demonstrated to induce Gasdermin E (GSDME)-mediated pyroptosis. This study aims to identify druggable targets and develop novel targeted radiosensitization strategies by focusing on GSDME.
methodsThe activation of GSDME-mediated pyroptosis by X-ray irradiation in ESCC cells was confirmed by microscopic observation, inflammatory cytokine release assays, and western blot analysis. To delineate the functional roles of GSDME following its knockdown and reconstitution in ESCC cells, we evaluated proliferation using cell counting and EdU assays, migration using wound healing and Transwell assays, and radiosensitivity using a combination of colony formation, Cell Counting Kit-8 (CCK-8), and propidium iodide (PI) staining assays. Mechanistic downstream signaling pathways were identified by western blotting and RNA sequencing, and pharmacological inhibition validated these mechanisms both in vitro and in nude mouse models.
resultsX-ray irradiation induced GSDME-mediated pyroptosis in ESCC cells. Notably, GSDME downregulation promoted tumor cell proliferation, migration, and radioresistance. Conversely, GSDME reconstitution reversed these phenotypes and restored radiosensitivity. Mechanistically, GSDME knockdown decreased the expression of signaling lymphocytic activation molecule factor 7 (SLAMF7), which further upregulated tumor necrosis factor receptor-associated factor 6 (TRAF6) and ultimately activated the NF-κB signaling pathway. Pharmacological inhibition of NF-κB with BAY 11-7082 in GSDME-low ESCC cells suppressed proliferation and migration, and enhanced radiosensitivity both in vitro and in vivo.
conclusionsGSDME functions as a tumor suppressor by enhancing radiosensitivity and inhibiting proliferation and migration in ESCC, through the suppression of the NF-κB signaling pathway. These findings nominate GSDME as a promising biomarker and the NF-κB signaling pathway as a therapeutic target for overcoming radioresistance in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.